News & Updates

In children with type 1 diabetes (T1D), glycated haemoglobin A1c (HbA1c) significantly decreases at 12 months after diagnosis with the help of a technology-enabled, team-based approach to intensified new-onset education involving target setting, continuous glucose monitoring (CGM), and remote data review, results of a study have shown.

Individuals at elevated cardiovascular disease risk (overweight/obese, increased blood pressure levels) may improve the duration and efficiency of their sleep through regular resistance exercise regimens, according to a study presented at the EPI Lifestyle Scientific Sessions 2022.

Rigorous monitoring is necessary among recipients of allogeneic haematopoietic stem cell transplantation (allo-HSCT) for the development of metabolic diseases, such as hypertension, diabetes, dyslipidaemia, and cardiovascular disease (CVD), suggests a recent study.

Subclinical hyperthyroidism (SHyper) does not independently correlate with major adverse cardiovascular events (MACE) in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI), results of a study have shown.

Type 2 diabetes patients who use sodium-glucose cotransporter 2 inhibitors (SGLT2is) see no increase in the risk of fractures, a recent Korea study has found.

Individuals who consume a moderate amount of wine with meals may have a reduced risk of new-onset type 2 diabetes (T2D), according to a study presented at the EPI Lifestyle Scientific Sessions 2022.

Individuals with severe insulin-resistant diabetes (SIRD) appear to have the lowest physical fitness compared with other diabetes subgroups despite similar endothelial function across all cohorts, a study has shown. Moreover, those with severe autoimmune diabetes (SAID) have the lowest cardiovascular risk within the first year following diagnosis relative to other clusters.

In individuals with type 2 diabetes (T2D), greater variability in adiposity indices (BMI and waist circumference [WC]) was tied to increased risk of cardiovascular disease (CVD) outcomes and death – but an intensive weight loss programme mitigated this risk, a study suggests.

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce hospitalization for heart failure (hHF) and all-cause death in type 2 diabetes mellitus (T2DM) patients without a history of cardiovascular disease, reports a new study.